To develop a cost-effectiveness analysis of formoterol associated to budesonide for maintenance and reliever therapy (FB SMART) versus salmeterol associated do fluticasone (SF) in the treatment of patients with moderate to severe persistent asthma, under the Brazilian societal perspective. METHODS: A Markov model was developed to project costs and outcomes associated with disease progression of patients with moderate to severe persistent asthma receiving SMART therapy or SF in a one year time horizon. Weekly cycles were considered and the model structure consisted of four possible health states: disease control, use of oral corticoids (OC), hospitalization/emergency visit (H/ER) and death. The probabilities of having severe exacerbations (OC or H/ER) were extracted from the study by Kuna et al. All cause mortality rates were obtained from national epidemiological databases. Adverse events were not significantly different between comparators so were excluded from the model. Outcomes were expressed as severe exacerbations avoided (SEA) and only direct medical costs were included in the analysis. Resource use during hospitalization was estimated based on an expert panel. Maximum prices to consumer were obtained for drugs, and procedure costs were extracted from the Brazilian Classification of Medical Procedures (CBHPM). RESULTS: In one year, the average number of severe exacerbations was 0.2436 in the SMART group and 0.3928 in the SF group, resulting in 0.1492 severe exacerbations avoided. Total cost for the SMART and SF groups were R$1823.56 and R$1417.49, respectively (incremental cost R$406.07). The incremental cost-effectiveness ratio in 1 year was R$2721/SEA (US$1944 2005-PPPindex USD1.0 R$1.4). The variables that most influenced the results were the costs of SMART and SF therapy and the cost of hospitalization. CONCLUSIONS: SMART therapy reduces the risk of severe exacerbations when compared to SF in patients with moderate to severe persistent asthma, at a reasonable incremental cost, being a valuable alternative for these patients.
PRS19 IS IT TIME FOR SMOKING CESSATION PRODUCTS TO BE REIMBURSABLE IN THAILAND?
Thavorn K 1 , Chaiyakunapruk N 2 1 University of Toronto, Toronto, Ontario, Canada, 2 Center of Pharmaceutical Outcomes Research, Mueng, Phitsanulok, Thailand OBJECTIVES: Currently, no smoking cessation product is listed on National Essential List of Essential Medicine in Thailand. This study aimed to evaluate the cost-effectiveness of non-nicotine smoking cessation products in Thailand from health care system perspective. METHODS: A Markov model was used to simulate the effects of smoking-cessation on cohorts of 10,000 male smokers age 40 who regularly smoked 10-20 cigarettes a day. An incremental cost-effectiveness ratio of varenicline, bupropion, and nortriptyline compared to self-quitting was estimated. Transition probabilities were obtained from literature reviews, while medical care costs and utilization patterns were derived from a database of a Thai tertiary-care hospital and from the literature. The efficacy of all three products was obtained from a Bayesian metaanalysis. Costs of the medications were obtained from the Thai Drug and Medical Supply Information Center. Both costs and outcome were discounted at three percent. All costs were presented in 2008 Thai Baht. A series of sensitivity analysis including probabilistic sensitivity analysis, and cost-effectiveness acceptability curve were performed. RESULTS: In comparison to self-quitting, using a non-nicotine smoking cessation product results in cost-savings. Varenicline use results in the highest cost savings of 21,187 Baht or approximately US$605 and life-years gain of 0.25 years. The use of nortriptyline and bupropion was shown to lead to similar magnitude of both life years saved and cost-savings. Nortriptyline and bupropion use had cost-savings of 11,506 Baht and 10,734 Baht, respectively. Probabilistic sensitivity analyses demonstrate that the probability of cost-saving from using nortriptyline, varinicline, and bupropion for smoking cessation were 99%, 85%, and 80%, respectively. CONCLU-SIONS: From the perspective of the health care system, using of any of the three products yielded cost-savings and life-year gains. These findings may persuade Thai policy-makers to consider including these smoking cessation products on the National List of Essential Medicine. To assess, in real life conditions, the costs, effects, and cost-effectiveness of Xolair® (omalizumab) as add-on versus conventional therapy in the management of Belgian patients with severe persistent allergic asthma inadequately controlled. METHODS: The same Markov model used for omalizumab initial reimbursement dossier was populated with data from a Belgian observational study, i.e. PERSIST study (n 160), especially set up to address questions raised by the Belgian authorities for omalizumab re-evaluation. The model takes into account four health states and links effectiveness data, real life resource use, and utility data. Medical resources use (drug treatment, laboratory tests and procedures, physician consultations, emergency room visits, and hospitalisations) were collected in PERSIST and costed from the perspective of the health care payer (i.e. INAMI/RIZIV patient). EQ-5D data were also collected during the study and used in the Markov model. RESULTS: Over a lifelong time horizon, the expected average numbers of life years (LYs) and QALYs per patient, for conventional therapy are 18.33 and 9.80, respectively. For omalizumab, the respective figures are 22.19 and 12.54. Over a lifelong time horizon, the expected average costs per patient are a44,548 and a124,726 for conventional therapy and omalizumab as add-on, respectively. Hence, omalizumab ICERs are a20,777/LY gained and a29,187/QALY gained. This compares very favourably (cf. substantial decrease in the ICERs) with the initial submission ICERs (i.e. a40,370/LY gained and a42,669/QALY gained). The sensitivity analyses performed show that results can somewhat vary according to the parameters changed. However, in all cases, the ICERs obtained with real life data are always markedly inferior to what was calculated in our initial submission. CONCLUSIONS: The pharmacoeconomic evaluation based on
PRS20 ECONOMIC EVALUATION OF THE IMPACT OF THE MEXICO CITY'S NON-SMOKERS HEALTH PROTECTION ACT
The pharmacoeconomic evaluation based on data from a real life Belgian study confirms that omalizumab is cost-effective versus conventional therapy in the treatment of patients with severe persistent allergic asthma inadequately controlled.
PRS22 COST-EFFECTIVENESS ANALYSIS OF TIOTROPIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN SPAIN.
Brosa M 1 , Díaz S 2 , Miravitlles M 3 , Gonzalez-Rojas N 4 , Nieves D 1 1 Oblikue Consulting, Barcelona, Spain, 2 Pfizer Spain, Madrid, Spain, 3 Hospital Clínic, Barcelona, Spain, 4 Boehringer Ingelheim, Sant Cugat del Vallés, Spain OBJECTIVES: The aim of this study is to analyze if tiotropium bromide is an efficient alternative respect to ipratropium bromide and standard therapy, in the management of chronic obstructive pulmonary disease (COPD) patients in Spain. METHODS: Efficiency of the different alternative options in COPD treatment was evaluated with a cost-effectiveness analysis. Tiotropium bromide was compared to ipratropium bromide and standard therapy by means of a cost-effectiveness analysis that estimates life years gained (LYG) with tiotropium respect to alternatives, by combining mortality associated to COPD exacerbations with rates of exacerbations taken from two meta-analysis of head to head clinical trials. The time horizon of the study was 13 years, the mean life expectancy in COPD patients included in the clinical trials with tiotropium. Uncertainty was studied by successive univariant sensitivity analysis of key parameters of the model and a probabilistic sensitivity analysis. All costs were expressed in a2008 and a 3% discount rate was applied to costs and effects. The analysis took the perspective of the Spanish National Health System (NHS). RESULTS: Incremental cost-effectiveness ratio (ICER) when treating COPD patients with tiotropium versus standard therapy was a2873/LYG, and in patients treated with tiotropium versus ipratropium bromide was a4208/LYG. Univariant sensitivity analysis showed that results where most sensitive to COPD severity and the future costs of surviving patients. CONCLUSIONS: Treating COPD patients with tiotropium is an efficient alternative respect ipratropium bromide or standard therapy for the Spanish NHS.
